Format

Send to

Choose Destination
See comment in PubMed Commons below
Mult Scler Int. 2011;2011:561262. doi: 10.1155/2011/561262. Epub 2011 Sep 12.

Reduced ErbB4 Expression in Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis.

Author information

1
Neuroimmunology laboratory, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler's Faculty of Medicine, Tel Aviv University, 64239 Tel Aviv, Israel.

Abstract

BACKGROUND:

There is an insufficient remyelination in the lesions of multiple sclerosis (MS). One of the factor that was found to promote remyelination is neuregulin-1 which is the ligand of ErbB4. Immune cells have been implicated in neurogenesis and oligodendrogenesis.

AIMS:

We studied the expression of ErbB4 in the immune cells of patients with relapsing remitting (RR) multiple sclerosis (MS) and healthy controls.

METHODS:

ErB4 expression in immune cells was studied by flow cytometry without stimulation or with stimulation with anti-CD3 and anti-CD28 monoclonal antibodies or in the presence of interferon-g or TNF-α as well as by immunoprecipitation and Western blot, and its mRNA was studied by real-time PCR.

RESULTS:

We found reduced levels of ErbB4 in the total PBMCs and in T cells, monocytes, and B cells of RR MS patients. Similarly, the ErbB4 RNA levels were reduced in the immune cells of patients with RR-MS. Stimulation via CD3 and CD28 significantly upregulated the expression of ErbB4 on immune cells healthy individuals. This effect was weaker in the patients group.

CONCLUSION:

ErbB4 may play a role in the proliferation of oligodendrocyte progenitor cells, differentiation of oligodendrocytes, and remyelination, and, therefore, the reduced ErbB4 expression in immune cells of patients with RR-MS may contribute to insufficient remyelination that occurs in the disease.

PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center